Marija Dimitrovska-Ivanova, Elena Simeonovska Joveva, Marija Karakolevska Ilova, Aneta Demerdzieva, Biljana Coneska Jovanova, Snezana Palcevska Kocevska
{"title":"Macroamylasemia in a Two-Year-Old Boy as the First Manifestation of Celiac Disease: A Case Report.","authors":"Marija Dimitrovska-Ivanova, Elena Simeonovska Joveva, Marija Karakolevska Ilova, Aneta Demerdzieva, Biljana Coneska Jovanova, Snezana Palcevska Kocevska","doi":"10.1159/000550670","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Macroamylasemia is a rare biochemical disorder in which the amylase molecule binds to other macromolecules, most commonly immunoglobulin A or G. The increased molecular weight of this complex reduces renal excretion of the enzyme, resulting in chronically elevated serum amylase levels. It can be associated with various non-pancreatic conditions, including celiac disease. In some reported cases, macroamylasemia resolved with a gluten-free diet. We present a pediatric case in which macroamylasemia was the initial manifestation of celiac disease.</p><p><strong>Case presentation: </strong>A two-year-old boy presented with a 3-month history of abdominal pain, anemia, and constipation. Physical examination revealed paraumbilical tenderness. Laboratory tests showed hypochromic anemia; elevated serum amylase (171 U/L); low serum iron (2.5 µmol/L); vitamin D3 deficiency (15.9 ng/mL), and low urine amylase with an amylase/creatinine clearance ratio below 1%, confirming macroamylasemia. Imaging studies were normal. HLA typing revealed the HLA-DQ2 haplotype. Celiac serology was positive for tissue transglutaminase-IgA (87.55 IE/mL) and endomysial antibody-IgA (1:>100). Duodenal biopsy confirmed Marsh type IIIb histology. A gluten-free diet was initiated alongside iron and vitamin D3 supplementation. Symptoms resolved within 2 months, accompanied by normalization of serum amylase levels and a weight gain of over 1 kg. Vitamin D3 therapy was continued until serum levels normalized.</p><p><strong>Conclusion: </strong>Celiac disease should be considered in patients with unexplained macroamylasemia, even in the absence of classical gastrointestinal symptoms. The primary treatment in such cases is a strict gluten-free diet, which can lead to the normalization of serum amylase levels when macroamylasemia is associated with celiac disease.</p>","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"20 1","pages":"40-45"},"PeriodicalIF":0.7000,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12995351/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000550670","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Macroamylasemia is a rare biochemical disorder in which the amylase molecule binds to other macromolecules, most commonly immunoglobulin A or G. The increased molecular weight of this complex reduces renal excretion of the enzyme, resulting in chronically elevated serum amylase levels. It can be associated with various non-pancreatic conditions, including celiac disease. In some reported cases, macroamylasemia resolved with a gluten-free diet. We present a pediatric case in which macroamylasemia was the initial manifestation of celiac disease.
Case presentation: A two-year-old boy presented with a 3-month history of abdominal pain, anemia, and constipation. Physical examination revealed paraumbilical tenderness. Laboratory tests showed hypochromic anemia; elevated serum amylase (171 U/L); low serum iron (2.5 µmol/L); vitamin D3 deficiency (15.9 ng/mL), and low urine amylase with an amylase/creatinine clearance ratio below 1%, confirming macroamylasemia. Imaging studies were normal. HLA typing revealed the HLA-DQ2 haplotype. Celiac serology was positive for tissue transglutaminase-IgA (87.55 IE/mL) and endomysial antibody-IgA (1:>100). Duodenal biopsy confirmed Marsh type IIIb histology. A gluten-free diet was initiated alongside iron and vitamin D3 supplementation. Symptoms resolved within 2 months, accompanied by normalization of serum amylase levels and a weight gain of over 1 kg. Vitamin D3 therapy was continued until serum levels normalized.
Conclusion: Celiac disease should be considered in patients with unexplained macroamylasemia, even in the absence of classical gastrointestinal symptoms. The primary treatment in such cases is a strict gluten-free diet, which can lead to the normalization of serum amylase levels when macroamylasemia is associated with celiac disease.